Collection Details : Oncology Times

Journal Logo


  • Creator:   Sarah LaCorte
  • Updated:   12/22/2022
  • Contains:  38 items
Oncology's top experts share their perspectives, opinions, and concerns about the field's most pressing issues covered in recent OT articles.

Duration: 30:06
Oncology Times 
Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make surgical resection difficult or impossible. This makes sarcoma exceedingly complex to diagnose and treat.

Today on OncTimes Talk, we interview Gary K. Schwartz, MD, and discuss treatment approaches for sarcoma, the fundamental needs of sarcoma patients, and how the oncology community at large can better understand this complex disease.

Schwartz is Chief of the Division of Hematology and Oncology at NewYork-Presbyterian/Columbia University Irving Medical Center and Associate Director of the Herbert Irving Comprehensive Cancer Center. With a clinical focus in melanoma and sarcoma, Schwartz is a recognized leader in the field of translational research and his work focuses on the identification of new targeted agents for cancer therapy.
Duration: 17:52
Oncology Times 

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new study, David Sallman, MD, from the Moffitt Cancer Center in Tampa, Florida, had reported the new findings at the 2022 Annual Meeting of the American Society of Hematology, OncTimes Talk correspondent Peter Goodwin interviewed him about the study and about the overall prospects of using CAR-T cells to treat AML.

PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence; and a kill switch to conditionally eliminate CAR-T cells for an improved safety profile. CD33 is over-expressed on AML blasts with lesser expression on normal hematopoietic stem cells. PRGN-3006 UltraCAR-T drug product is manufactured via an overnight process at medical centers using the Company's proprietary non-viral and UltraPorator systems and released for infusion in patients the next day. The decentralized, overnight UltraCAR-T manufacturing process, which does not use viral vectors or ex vivo activation and expansion of T cells, has the potential to address major limitations of current T cell therapies. PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation and Fast Track Designation in patients with AML by the FDA.

The Phase I/Ib clinical study is designed to enroll in two phases, an initial dose escalation phase followed by a dose expansion phase, to evaluate safety and determine the recommended Phase II dose of PRGN-3006 delivered via intravenous (IV) infusion without lymphodepletion (Cohort 1) or with lymphodepletion (Cohort 2). The study is also evaluating in vivo persistence and anti-tumor activity of PRGN-3006.

Duration: 24:47
Oncology Times 

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and costs can be prohibitive. An alarming trend has also emerged, with incidence of early-onset colorectal cancer increasing over the last few decades.

Today on OncTimes Talk, we interview Anil K. Rustgi, MD, on the current state of colorectal cancer screening, advancements in non-invasive testing, and the mechanisms behind early-onset colorectal cancer.

In addition to being a world-renowned leader in the field of gastrointestinal oncology, Rustgi is the Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center. His research focuses on tumor initiation, the tumor microenvironment, and tumor metastasis in gastrointestinal cancers.

Duration: 11:25
Oncology Times 

BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) 2022 Symposium on Molecular Targets and Cancer Therapeutics.

Marco Tagliamento, PhD student, medical oncologist, and research fellow at the Gustave Roussy Institute, France, told the symposium about study findings from the large Gustave Roussy Molecular Tumor Board dataset able to identify genetic mutations involved in clonal hematopoiesis. Tagliamento told the conference 113 patients—8 percent of their total—were found to have had at least one clonal hematopoiesis mutation that could be considered to place them at higher risk of developing hematologic malignancies.

“Out of these patients, 45 were referred to our hematology unit by their oncologist and five were subsequently diagnosed with blood cancer: one with myelomonocytic leukemia, two with myelodysplastic syndrome and two with essential thrombocythemia,” Tagliamento told the symposium.

Journalist Peter Goodwin briefly interviewed Tagliamento on his findings at EORTC-NCI-AACR.

Duration: 10:51
Oncology Times 

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics.

Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial, and salivary gland cancers. Tumors remained stable in just over half of the remaining patients. The presenting author at the Barcelona symposium, Carolyn McCourt, MD, Associate Professor of Obstetrics and Gynecology at Washington University in St. Louis, talked with OncTimes Talk reporter Peter Goodwin.

Duration: 25:46
Oncology Times 

In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cancer Society’s update on breast cancer statistics in the United States.

What is the underlying cause of disparities in breast cancer? It comes down to a variety of factors, from screening disparities and clinical trial participation to differences in genetics and biology. Today on OncTimes Talk, we sit down with Lisa A. Newman, MD, MPH, FACS, FASCO, to discuss each of these categories and explore how oncologists and the medical community at large can finally close the gap.

Newman is a world-renowned surgical oncologist and was appointed Chief of the Section of Breast Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine. She also leads the multidisciplinary breast oncology programs at the NewYork-Presbyterian David H. Koch Center, providing compassionate care to breast cancer patients. Newman’s primary research has focused on ethnicity-related variation in breast cancer risk and management of high-risk patients.

Duration: 14:56
Oncology Times 
We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. The disease carries a poor prognosis, and although it has been treated with combination leukemia or lymphoma chemotherapy regimens, these often result in nondurable responses with high rates of relapse.

Oncology Times journalist Catlin Nalley sat down with Pemmaraju to discuss his most recent study titled “Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm,” recently published in the Journal of Clinical Oncology (2022; doi: 10.1200/JCO.22.00034). Pemmaraju is Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center and has dedicated his career to the study of rare and ultra-rare cancers.
Duration: 14:22
Oncology Times 
Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates mechanisms responsible for aging and cardiovascular pathologies. We discuss the unique characteristics of his patient population, new cardio-oncology devices and treatment options, and the ongoing obstacle of medical skepticism.
Duration: 9:22
Oncology Times 
PARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no standard therapy had yet been recommended and for which there had been a clear unmet need.

A team from Germany presented new findings from a randomized study using nirogacestat, a “NOTCH inhibitor”—gamma secretase inhibitor—that the investigators suggest should be adopted as standard therapy. This is pertinent to oncology practices since desmoid tumors have often been treated as if they were sarcomas in the absence of proven therapies, and there is a risk that inappropriate therapy can worsen outcomes with desmoid tumor.

Peter Goodwin caught up with principal author Bernd Kasper, MD, from Mannheim University in Heidelberg, Germany to get the details for OncTimes Talk.
Duration: 10:17
Oncology Times 
The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use as a means of spotting a wide range of cancers early—including types for which there is currently no routine screening (Abstract 903O). At the European Society for Medical Oncology 2022 Annual Congress, she told OncTimes Talk reporter Peter Goodwin about the findings which give her confidence that widespread blood testing could play an important role in the overall battle against cancer.
Duration: 46:01
Oncology Times 
Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts:

1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC:

David Cescon, MD, PhD, Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada discusses analysis of patient-reported outcomes in the KEYNOTE-355 study in which adding pembrolizumab immunotherapy to chemotherapy did not impair health-related quality of life among patients with previously untreated, programmed death-ligand 1 (PD-L1) -positive advanced, triple negative breast cancer (TNBC). :

2. Combination Therapy to Convert Immunologically “Cold” Breast Tumors into “Hot” Ones:

Alex De Caluwe, MD, Radiation Oncologist at the Institut Jules Bordet in Brussels, Belgium tells us about after his group’s findings from a “safety run-in” of the Neo-CheckRay study which raise hopes that immunologically “cold” breast cancers that do not respond to the new immune therapies such as checkpoint inhibitors could be converted into “hot” tumors, that could potentially be cured by them. :

3. Multidisciplinary Precision Extends Life with Breast Cancer Oligometastatic Disease:

Philip Poortmans, MD, PhD, from the University of Antwerp in Belgium, Senior Staff Member in the Iridium Netwerk’s Radiation Oncology Department, who chaired the “Multidisciplinary Tumour Board” session on Oligometastatic Diseases, tells us how a multidisciplinary approach targeting more than a single site of metastasis could bring significant gains in overall survival to patients whose breast cancer can be described as oligometastatic (having limited spread). :

4. Multidisciplinary Teams Can Help Many Breast Cancer Survivors Start Families:

Radiation Oncologist Orit Kaidar-Person, MD, Head of the Breast Cancer Unit at the Sheba Medical Center in Tel Hashomer, Ramat Gan, in Israel, tells OncTimes Talk why powerful new data about pregnancy outcomes among women who have survived breast cancer support the choice many of them take of going ahead with a pregnancy despite facing breast cancer treatment and uncertainties about their future health.
Duration: 17:14
Oncology Times 
In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens.

In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy.

Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS study investigators: Consultant Clinical Oncologist Vincent Khoo.
Duration: 27:55
Oncology Times 
CAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, to learn about giant steps forward for lung cancer management—reported in the Annals of Oncology—made with the sensitive assay for circulating tumor DNA (ctDNA) they developed (2022;

Rosenfeld tells reporter Peter Goodwin about the origins of his group’s genomic detection platform, and about the advances the assay has made for predicting non-small cell lung cancer relapse after primary treatment. He explains how the method provides a much clearer picture of whether the patient has residual disease, while also answering questions about what actionable mutations there are for patients with advanced cancers.
Duration: 10:16
Oncology Times 
At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was successful in detecting measurable residual disease (MRD) prior to late clinical metastatic recurrence in women with high-risk, HR-positive, HER2-negative breast cancer (Abstract 103).
Duration: 9:31
Oncology Times 

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvania Health System, during her poster session. Her research examined the feasibility and acceptability of a weight loss group program via telehealth for breast cancer survivors.

Duration: 18:42
Oncology Times 

Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve into our growing understanding of this area, including current and future research endeavors, and examine how germline predisposition intersects with disparities in cancer care. Godley is the Hospira Foundation Professor of Medicine and Human Genetics at The University of Chicago Medicine, and Keiffer is board certified in Internal Medicine, Hematology, and Oncology at Jefferson Health in New Jersey.

Duration: 34:15
Oncology Times 

As Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer. Today on OncTimes Talk, we review the war in Ukraine and discuss how the war is impacting cancer patients and health systems in neighboring countries. Trying to process the refugee flow is very daunting because “the numbers are absolutely staggering,” according to Richard Sullivan, MD, PhD, a member of the World Health Organization Emergency Committee, as well as Director of the Institute of Cancer Policy at King’s College, London. Sullivan gave a briefing on the developing situation in Ukraine during an ASCO/ECO webinar titled “Cancer Care During the War in Ukraine,” on March 18.

Later in the episode, we interview Deborah Mukherji, MD, MBBS, FRCP, at the American University of Beirut to discuss the experiences of refuges in Syria and Lebanon and how humanitarian and health agencies around the world can better serve displaced people.

Duration: 22:24
Oncology Times 

A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducing breast cancer risk, doctors still have to consider patients' choices which often involve other factors. For the individual patient, choosing a mastectomy is a complex non-linear process that is affected by personal knowledge, past experiences, and emotions surrounding identity and societal expectation.

To understand these factors more, Oncology Times interviewed Clara N. Lee, MD, Associate Professor of plastic and reconstructive surgery at The Ohio State University College of Medicine. Lee’s clinical practice focuses on breast reconstruction and microvascular surgery and her research focuses on understanding and improving how people with cancer make decisions about surgery. She recently authored a paper titled “The Role of Emotion in Cancer Surgery Decisions: Applying Concepts From Decision Psychology” published in the Annals of Surgery (2021; doi: 10.1097/SLA.0000000000004574). She has expertise in patient-reported outcomes for breast reconstruction and patient decision-making about breast cancer treatments. We discussed a bit of her research into the emotional journeys of patients who are deciding whether to proceed with contralateral prophylactic mastectomy

Duration: 15:08

While the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change will impact oncology practice and care is still emerging. We do know that climate change will impact cancer risk, increase exposure to carcinogens, impede access to care, and ultimately effect survival.

To discuss some of these impending changes and what oncologists and patients can do to prepare, Oncology Times interviewed Robert A. Hiatt, MD, PhD, Professor in the Department of Epidemiology and Biostatistics, and Associate Director of Population Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center.

Duration: 14:01

In early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save lives. The ambitious, jumpstarted Cancer Moonshot aims to reduce the U.S. death rate due to cancer by at least 50 percent over the next 25 years, and to improve the lives of all Americans living with and surviving cancer.

The recharged Cancer Moonshot calls for a bipartisan across-the-board, all-hands-on-deck U.S. effort, which includes establishing a “Cancer Cabinet” consisting of the heads of major government agencies. Biden is asking Congress to approve $6 billion net new money to advance promising new treatments.

In a press briefing in early February, Candace Johnson, PhD, the President and CEO of Roswell Park Comprehensive Cancer Center discussed the reinvigorated Moonshots program with Congressman Brian Higgins (D-NY 26th District). Roswell Park Comprehensive Cancer Center will benefit from the newly announced federal Cancer Moonshot Initiative and Representative Brian Higgins said the center was selected because of its extraordinary background in cancer research and treatment.

Duration: 41:47

Today we revisit three studies presented at the ASH 2021 Annual Meeting.

Primary Analysis of ZUMA-7
The 2021 American Society of Hematology Plenary Sessions in Atlanta, Georgia, heard data from a new study of CAR-T cell therapy in patients with diffuse large B-cell lymphoma: the Phase III randomized ZUMA-7 trial. This compared Axicabtagene Ciloleucel (Axi-Cell) with the current standard-of-care in patients whose disease had relapsed or was refractory after first-line therapy.

After the talk, Oncology Times reporter Peter Goodwin caught up with the lead investigator Frederick Locke, MD, Co-Leader of the Immuno-Oncology Program, and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at the Moffitt Cancer Center in Tampa, FL.

How Patients with AML & MDS Respond to COVID Vaccines
ASH 2021 held a cluster of sessions devoted to coronavirus infection in patients with hematologic malignancies.

Since cancer patients in general are at higher risk from COVID-19 than the general population, it has become vitally important to know whether vaccines can protect them.

Vaccine responses in patients with myelodysplastic syndrome and acute myeloid leukemia have been investigated by a team led by Jeffrey Lancet, MD, Chair of Malignant Hematology at the Moffit Cancer Center in Tampa, Florida.

Oncology Times reporter Peter Goodwin asked him about his findings.

Antibody Response to Vaccination

Whether or not to vaccinate your patient for COVID-19 may not be obvious in some clinical situations, and in hematologic malignancy this cannot be assumed.

At ASH, German investigator Susanne Saussele, MD, reported her group’s findings about vaccination responses in patients with a range of myeloid and lymphoid malignancies. She is Head of the CML Excellence Center III. Medizinische Klinik, Hematology and Oncology at the University of Mannheim in Mannheim, Germany.

Duration: 66:19

Today we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto a story on how radiotherapy can cut late gastrointestinal toxicity for cervical cancer patients, and finish with lessons on what COVID has taught us about cancer care. All interviews are brought to you by journalist Peter Goodwin.

First up, we hear from radiation oncologist Stephen Hahn, MD, who was the U.S. Food and Drug Administration's Commissioner from 2019 to 2021—where he oversaw all manner of regulations concerning COVID-19 vaccines and therapeutics. In his 2021 address at the World Cancer Leaders' Summit, Hahn discussed "What can we learn from the development of COVID-19 vaccines." During the summit, leading cancer decision-makers from about a hundred countries met online to assess whether innovations generated during the pandemic of COVID-19 could be harnessed to improve cancer treatment and prevention. Journalist Peter Goodwin was curious to know about decision-making at the FDA during this crucial period of American history.

Next, from Mumbai, India—there's news that the new adjuvant radiotherapy standard of care for cervical cancer—image-guided intensity-modulated radiotherapy (IG-IMRT)—should cut late gastrointestinal (GI) toxicity rates by 50 percent. This according to mature results from the Phase III, randomized Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) study.

Although IG-IMRT is a newer—more costly—form of radiotherapy that has already been shown to reduce early toxicity rates to some extent when compared with conventional three-dimensional conformal radiation therapy (3D-CRT), up until now it had not been shown to outperform the older technique either in terms of medium-term toxicity or anti-cancer activity.

The PARCER findings, however, demonstrate clear superiority for long term GI toxicity. They confirm equivalent anti-neoplastic efficacy.

Peter Goodwin interviewed first author Supriya Chopra MD, DNB, from the Tata Memorial Centre’s Homi Bhabha National Institute in Kharghar near Mumbai, India. She discusses the strong mandate that the study has brought for choosing IG-IMRT adjuvant radiotherapy for patients with early cervical cancer in whom surgery is needed.

Lastly, The COVID-19 pandemic has taught us a lot about cancer care—according to one of India's most prominent oncologists, C.S. Pramesh, MS FRCS, Director of the Tata Memorial Centre in Mumbai, India. He also spoke at the 2021 World Cancer Leaders’ Summit, organized by the Union for International Cancer Control, and hosted virtually by the American Society for Clinical Pathology. After the meeting OncTimes Talk reporter Peter Goodwin caught up with him to ask for his take on the impact the pandemic has had on cancer medicine, and about his views on how to improve medical practice and cope better with future crises.

Duration: 18:41
Oncology Times 

At the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute leukemia or myelodysplastic syndrome and have become infected with COVID-19. In a key study presented at ASH, Dr. Pinkal Desai from New York’s Weill Cornell Medical College has identified clinical predictors of outcome among these patients. Oncology Times reporter Peter Goodwin talked with Dr. Desai about her findings and clinical recommendations.

Duration: 17:53
Oncology Times 
In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient’s—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the UK, using the refined genetic sequencing tool: single cell multi omics (Abstract 3). The ASH Plenary Session heard an inspiring talk on this from Oxford scientist Alba Rodriguez-Meira—winner of an ASH Abstract Achievement Award. And after the session, OT reporter Peter Goodwin tracked down her colleague, senior author Adam J. Meade, at the Weatherall Institute of Molecular Medicine in Oxford University.
Duration: 14:49
Oncology Times 

A new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully vaccinated. The real-world, retrospective cohort study included data from 3.4 million Californian residents and was recently published in The Lancet. 

The importance of this Californian study is that up until now we've mainly relied on phase three study results to assess vaccine efficacy. This study (and another, even bigger one in Chile—with the CoronaVac) brings much greater statistical significance to the outcome findings and makes it possible to look at subgroups.

In this episode, Lead author Dr. Sara Y Tartof, a Research Scientist Epidemiologist with Kaiser Permanente Department of Research & Evaluation in Southern California discusses the implications for vaccination programs with Oncology Times reporter Peter Goodwin.

Creator: Sarah LaCorte
Duration: 20:58
Colleague Conversations offers insights into hematology/ oncology from two different perspectives: a seasoned hematologist/oncologist and an early-career clinician. In this installment, Oncology Times sat down with Christopher A. Jones, MD, MBA, HMDC, FAAHPM, and David Jonathan Casarett, MD, MA, FAAHPM, to discuss the relatively new field of palliative care. The discussion leads us through how the field has transformed oncology care, how palliative care physicians can address issues like racial disparities, and how telehealth is the wave of the future.
Creator: Sarah LaCorte
Duration: 16:52
A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado School of Medicine, on the recent findings.
Creator: Peter Goodwin
Duration: 39:47

What’s in the OncTimesTalk, May 2021 Edition?

New clinical findings on:
Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breast cancer, COVID-19 vaccination limitations, sitagliptin/graft-versus-host disease, breast cancer individualization, neo-adjuvant chemotherapy for rectal cancer.
Ronan Kelly (Austin TX), Erica Mayer (Boston MA), Sibylle Loibl (Frankfurt, Germany), Shabir Madhi (Johannesburg South Africa) and Thierry Conroy (Nancy, France).

Interviews in this edition:

Ronan J Kelly MD MBA, Baylor University Medical Center, Dallas
Adjuvant Nivolumab “Practice Changing” in Resected Gastroesophageal Cancer
Ronan Kelly tells OncTimesTalk about a big reduction in the risk of death, and doubling of median disease-free survival, from using nivolumab as adjuvant therapy for patients with esophageal, and gastro-esophageal junction, cancers after
chemoradiotherapy plus surgery in the placebo-controlled phase-three CheckMate 577 study.

Erica L. Mayer MD, Dana-Farber Cancer Institute, Boston, MA
Palbociclib Added No Benefit to Breast Cancer Adjuvant Endocrine Therapy
Erica Mayer discusses the PALLAS study findings with OncTimesTalk that adding the CDK 4/6 inhibitor palbociclib to endocrine therapy failed to improve invasive disease-free survival among patients with early breast cancer despite its proven efficacy in metastatic disease.

Breast Cancer: A Guide to Therapy Individualization 
Sibylle Loibl, Professor of Obstretrics and Gynaecology, University of Frankfurt, CEO and Chair, German Breast Group.
Sibylle Loibl discusses her expert panel’s findings with OncTimesTalk about optimizing the many powerful methods for managing breast cancer to individualize treatment. “Future research in breast cancer will focus not only on new drugs, but even more on the individualization of therapy for every single tumor in every single patient,” she wrote in “The Lancet”.

Sherif S. Farag MD PHD, Director of the Stem Cell Transplant and Cellular Therapy, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, in Indianapolis
Sitagliptin Reduced Graft Versus Host Disease in Stem Cell Transplantation
A non-randomized 36-patient phase-two clinical study found a big reduction in acute graft-versus-host disease after adding the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (a long established antiglycemic agent) to immunosuppression for allogeneic stem-cell transplantation.  Sherif Farag discusses the study findings with OncTimesTalk.

Shabir A. Madhi PhD, Professor of Vaccinology and Director of the Vaccines & Infectious Diseases Analytics Research Unit at the University of Witwatersrand in Johannesburg, Co-Director of African Leadership in Vaccinology Expertise.
SARS-CoV-2 Vaccine Was Ineffective Against B.1.351 (“South African”) Variant
A “first-generation” vaccine for COVID-19 failed to prevent mild or moderate disease caused by the B.1.351 coronavirus variant in South Africa in a randomized, double-blind, controlled trial of the ChAdOx1 nCoV-19 vaccine among relatively young adults. Shabir Madhi tells OncTimesTalk, however, that vaccination with such first-generation vaccines should still protect against severe disease and death from the new variant because T-cell responses had been preserved in the South African variant.

Thierry Conroy MD, Professor, Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54519 Vandoeuvre-lès-Nancy, France
Neoadjuvant Chemotherapy Before Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
A multi-center, randomized, open-label, phase-three trial has shown that outcomes for patients with rectal cancer can be improved still further by using neoadjuvant chemotherapy before the current standard of care (chemo-radiotherapy and surgery).  Professor Thierry Conroy, from the Cancer Institute in Nancy, gives OncTimesTalk the details on why they decided to try an additional treatment and the benefit it brought.

Creator: Oncology Times
Duration: 13:28
Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. Today Dr. Bolwell revisits his Oncology Times column on “Values” and outlines how to grow from an individual-focused, emotion-based values system to living with more positive values.
Creator: Sarah LaCorte
Duration: 10:48
Liam Holt, PhD, speaks in analogies when describing his work focusing on compression of cancer cells and how it affects their behavior and evolution at his lab at the Institute for Systems Genetics at NYU Grossman School of Medicine. The assistant professor in the Department Of Biochemistry and Molecular Pharmacology aims to characterize how compression of cells causes genome instability specifically in pancreatic cancer.
Creator: Oncology Times
Duration: 15:05
In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.
Creator: Sarah LaCorte
Duration: 12:46
Oncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. In his recurring Oncology Times column Straight Talk: Today's Cancer Centers, Dr. Bolwell dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell discusses the art of forgiveness; including how to let it go when there is conflict and breach of trust.
Creator: HemOnc Times
Duration: 3:57
Oncology Times 
HemOnc Times Editorial Advisory Board Member Margaret ‘Margie’ Kasner, MD, MSCE, of Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, shares her passion for the field of hematology/oncology as well as one of her most memorable patient experiences.
Creator: HemOnc Times
Duration: 9:19
Oncology Times 
Naveen Pemmaraju, MD, discusses the therapeutic landscape of ultra-rare cancers as well as the importance of ongoing research in these patient populations. Additionally, he shares his own passion for this area of study and how it has shaped his career.